treatment protocol to follow with drugs and dosage in detail for fip in cats
Reading File
Finding Sources
Searching PubMed
feline infectious peritonitis GS-441524 treatment protocol
Searching the Web
FIP cat treatment protocol GS-441524 GC376 dosage 2024 2025 guidelines
Reading Web Page
https://icatcare.org/resources/icatcare_fip_update_july25.pd…
Reading Article
PMID: 40732763
Here is a detailed, up-to-date treatment protocol for FIP in cats, based on the July 2025 International Cat Care (iCatCare) update, ISFM guidelines (Taylor et al., 2025), ABCD guidelines, and a 2025 systematic review (Gokalsing et al., Pathogens) covering 650 treated cases.
FIP Treatment Protocol in Cats (2025)
1. Background
FIP is caused by a virulent mutant of feline coronavirus (FCoV). It was almost universally fatal until the development of nucleoside analog antivirals. Current treatment achieves >84-90% sustained remission when appropriate protocols are followed.
Two drug classes are used:
- GS-441524 - adenosine analog nucleoside; the primary drug
- GC376 - 3C-like protease inhibitor; used as adjunct or in refractory/neurological cases
- Remdesivir (prodrug of GS-441524) - IV/SC for critical cases
2. Diagnosis Before Starting Treatment
Before initiating antivirals, confirm FIP. Key diagnostics:
| Test | Finding in FIP |
|---|---|
| Effusion fluid analysis | High protein, low cellularity; Rivalta test positive |
| Albumin:Globulin ratio | <0.4 (strongly suggestive) |
| Alpha-1 acid glycoprotein (AGP) | Markedly elevated (>1.5 mg/mL) |
| Serum amyloid A (SAA) | Elevated |
| PCR (effusion or CSF) | FCoV RNA positive |
| Immunofluorescence / immunohistochemistry | FCoV antigen in macrophages |
| CBC/Biochemistry | Lymphopenia, elevated globulins, elevated bilirubin |
3. Classifying FIP Form
The correct drug dose depends on the FIP presentation:
| Form | Description |
|---|---|
| Wet (effusive) | Peritoneal, pleural, or pericardial effusion |
| Dry (non-effusive) | Granulomatous lesions in organs, lymph nodes |
| Ocular FIP | Uveitis, hypopyon, aqueous flare |
| Neurological FIP | Ataxia, seizures, nystagmus, paresis, hyperesthesia |
| Mixed | Combinations of the above |
4. Primary Drug: GS-441524
Oral GS-441524 (first-line for most cats)
Available as tablets (50 mg) and suspension (50 mg/mL). Give on an empty stomach (30+ minutes before food). Tablets can be crushed and given in a small treat.
| FIP Form | Dose | Frequency |
|---|---|---|
| Wet or Dry FIP - no ocular/neurological signs | 15 mg/kg/day | q24h OR split as 7.5 mg/kg q12h |
| Ocular FIP (± effusion) | 20 mg/kg/day | Split as 10 mg/kg q12h preferred |
| Neurological FIP (± effusion) | 20 mg/kg/day (minimum) | 10 mg/kg q12h (q12h mandatory) |
Notes:
- q12h dosing improves plasma concentrations and is recommended for ocular and neurological forms
- Some clinicians use a uniform 15 mg/kg q24h for all forms (Zuzzi-Krebitz protocol); success reported with intensive monitoring
- Adjust dose with every weight gain (weigh weekly)
Injectable Remdesivir (for critical/non-ambulatory cats)
Used when the cat cannot be orally medicated: severe neurological symptoms, inability to swallow, severe dehydration, or critically ill.
| FIP Form | Remdesivir IV or SC Dose | Frequency |
|---|---|---|
| Wet/Dry - no ocular/neurological signs | 10 mg/kg | q24h IV or SC |
| No effusion - no ocular/neurological signs | 12 mg/kg | q24h |
| Ocular signs present | 15 mg/kg | q24h |
| Neurological signs present | 20 mg/kg | q24h |
Transition to oral GS-441524 as soon as the cat is stable and able to swallow.
Subcutaneous GS-441524 (injectable, where available)
SC dosing is approximately half the oral dose (oral bioavailability is lower):
| FIP Form | SC Dose | Frequency |
|---|---|---|
| Wet/Dry - no ocular/neurological | 6-7.5 mg/kg | q12h |
| Ocular FIP | 8-10 mg/kg | q12h |
| Neurological FIP | 10 mg/kg (minimum) | q12h |
5. Treatment Duration
- Standard course: 84 days (12 weeks) of continuous antiviral treatment
- Shorter courses (42-56 days) have been used in mild, well-responding wet FIP but 84 days is the recommended standard
- Do not stop treatment until the cat has been clinically normal AND bloodwork (especially AGP/SAA and CBC) has been normal for at least 2 consecutive weeks
6. Adjunct Drug: GC376 (Protease Inhibitor)
Indications:
- Refractory cases (inadequate response after dose optimization)
- Viral resistance suspected (lack of expected improvement)
- Neurological FIP as combination with GS-441524
Dosing:
| Scenario | GC376 Dose | Route | Frequency |
|---|---|---|---|
| Added to GS-441524 (resistance/refractory) | 20 mg/kg | SC | BID (q12h) |
| Inadequate response to 20 mg/kg SC BID | Increase by 10 mg/kg increments | SC | BID, up to 50 mg/kg SC BID |
Note: GC376 is not recommended as monotherapy - always combine with GS-441524 or another nucleoside analog. It is associated with dental enamel defects in kittens under 4 months, so use with caution in very young cats.
7. Nirmatrelvir (Emerging Adjunct - 2025/2026)
Per ABCD 2025/2026 data, nirmatrelvir (Paxlovid component) has been used as an adjunct in refractory neurological FIP when added to GS-441524 or molnupiravir. In a small case series, 7/7 cats survived with combination therapy; the one cat given nirmatrelvir alone died. Doses ranged from 7.4 mg/kg. Not yet standard of care - use only in truly refractory cases with specialist guidance.
8. Monitoring Protocol
| Timepoint | Action |
|---|---|
| 48-72 hours | Phone check-in: appetite returning? fever resolved? |
| 2 weeks | Clinic visit: weight, clinical exam, CBC/biochemistry, AGP or SAA; if effusion still present, increase dose by 5-10 mg/kg/day and switch to q12h if on q24h |
| 4-6 weeks | Repeat bloodwork; confirm improving trends |
| 8-10 weeks | Repeat bloodwork; confirm clinical remission |
| End of treatment (day 84) | Full bloodwork must be normal before stopping |
| Post-treatment: weeks 1, 4, 8, 12 | Monitor for relapse (clinical signs, AGP/SAA) |
Expected early response: Appetite and energy improve within 2-5 days; fever resolves. Effusions begin resolving within 1-2 weeks. Lymphopenia and globulin levels normalize over weeks.
Therapeutic Drug Monitoring (TDM): Now available (e.g., University of Edinburgh, UK). Blood sampled after 3-5 doses at peak (2-3 hrs post-dose) or trough (9-12 hrs post-dose). Useful for dose optimization, especially in ocular/neurological cases with poor response.
9. Handling Relapse
Relapse during treatment:
- Increase GS-441524 dose by 5-10 mg/kg/day
- Switch to q12h dosing if currently on q24h
- Do not stop treatment until clinical and lab parameters have been normal for at least 2 weeks
- If new ocular or neurological signs develop, escalate to the neurological dosing protocol
Relapse after completing treatment:
- Restart GS-441524 at a higher dose (minimum 20 mg/kg/day, split q12h)
- Treat for another 12 weeks
- Consider adding GC376 if suspected resistance
10. Supportive Care
| Intervention | Indication |
|---|---|
| Effusion drainage | Large pleural effusions causing respiratory distress; abdominal drainage if significant discomfort |
| Nutritional support | Appetite stimulants (mirtazapine 1.875 mg/cat q48h), assisted feeding if needed |
| Corticosteroids | Prednisolone 1-2 mg/kg/day PO short-term only in severe inflammatory disease (neurological FIP, severe effusive disease) to reduce inflammation; taper quickly once antivirals take effect |
| Anti-nausea | Maropitant 1 mg/kg SC/PO q24h if vomiting |
| Fluids | IV crystalloids in dehydrated/critical patients |
| Eye drops | Topical steroids/atropine for uveitis (in addition to systemic antivirals) |
11. Observation Period After Treatment
After completing the full antiviral course:
- A 12-week observation period is recommended before declaring remission
- Recheck every 4 weeks (clinical exam + bloodwork)
- Relapse is most likely in the first month after completing treatment
- If no relapse after 12 weeks of observation with normal bloodwork, the cat is considered in sustained remission
12. Drug Availability Note
- Licensed oral GS-441524 (e.g., Lynx, Bova compounded formulations) is available in many countries including the UK, Australia, EU, and parts of Asia
- Remdesivir (Veklury) is available by prescription off-label in most countries
- GC376 remains largely research/compounded
- Use quality-assured, legally available preparations where possible; black-market products have variable quality and concentration
Summary dosing table (oral GS-441524):
| FIP Type | Daily Dose | Split Dose |
|---|---|---|
| Wet/Dry (no ocular/neuro) | 15 mg/kg q24h | 7.5 mg/kg q12h |
| Ocular FIP | 20 mg/kg/day | 10 mg/kg q12h (preferred) |
| Neurological FIP | 20 mg/kg/day minimum | 10 mg/kg q12h (mandatory) |
Source references: iCatCare FIP Update July 2025 | ABCD FIP Guideline | Gokalsing et al. 2025 Systematic Review (PMID 40732763) | Taylor et al. ISFM Guidelines 2025
Disclaimer: This protocol is for veterinary professional reference. All treatment decisions should be made by a licensed veterinarian with direct knowledge of the patient. Dosages and protocols evolve - consult current ISFM/iCatCare guidelines and a feline medicine specialist for complex cases.
basmi inj prorotocal
Asking for Preferences
Searching the Web
BASMI injectable GS-441524 FIP cats injection protocol dosage subcutaneous 2024 2025
Reading Web Page
https://www.basmifipindia.com/post/gs441524-dosage-guide-for…
Basmi FIP - Injectable GS-441524 Protocol
Basmi FIP is a brand of injectable GS-441524 widely used in Southeast Asia and India for FIP treatment. Here is the complete injection protocol:
Step 1 - Choosing the Right Vial Concentration
Basmi FIP GS-441524 injectable is available in multiple concentrations. Concentration choice affects injection volume - not efficacy (all have equal potency):
| Concentration | Best For |
|---|---|
| 15 mg/mL | Small cats, lower dose cases (wet/dry FIP without neuro signs) |
| 20 mg/mL | Standard weight cats |
| 30 mg/mL | Heavier cats, neurological/ocular FIP (smaller injection volume = more comfortable) |
Use a higher concentration vial for cats requiring higher doses or larger body weight - this keeps the injection volume small and reduces discomfort.
Step 2 - Dosage by FIP Type (SC Injection)
| FIP Form | Basmi Injectable Dose | Frequency |
|---|---|---|
| Wet FIP (effusive, no neuro/ocular) | 6 mg/kg | SC, once daily (q24h) |
| Dry FIP (non-effusive, no neuro/ocular) | 8 mg/kg | SC, once daily (q24h) |
| Ocular FIP | 10 mg/kg | SC, once daily (q24h) |
| Neurological FIP | 10 mg/kg | SC, q12h preferred |
How to calculate injection volume:
Volume (mL) = [Cat weight (kg) × Dose (mg/kg)] ÷ Concentration (mg/mL)
Example: 4 kg cat with Wet FIP, using 15 mg/mL vial:
- 4 kg × 6 mg/kg = 24 mg needed
- 24 mg ÷ 15 mg/mL = 1.6 mL per injection
Step 3 - Injection Technique (Subcutaneous)
- Site: Scruff of the neck or loose skin between shoulder blades (rotate injection sites daily)
- Needle: 25-27 gauge, 1/2 inch
- Temperature: Bring vial to room temperature before injecting (reduces sting)
- Speed: Inject slowly - rapid injection causes more pain
- After injection: Gently massage the site to disperse the medication
- Disposal: Use a new needle and syringe every injection; dispose safely
Important: SC GS-441524 injections can be painful. If the cat shows significant distress at injection site, consider switching to oral GS-441524 (double the SC dose) if available, or consult your vet about IV remdesivir for critical cases.
Step 4 - Treatment Duration
| Phase | Duration |
|---|---|
| Full antiviral treatment course | 84 days (12 weeks) - continuous, no days missed |
| Observation period after treatment | 84 days (12 weeks) - monitor for relapse |
- Do not stop early. Stopping before 84 days is a leading cause of relapse.
- Before stopping, confirm bloodwork (CBC, globulins, AGP/SAA) is fully normal for at least 2 consecutive weeks.
- Adjust dose upward with every weight gain during treatment.
Step 5 - Monitoring During Treatment
| Timepoint | Action |
|---|---|
| Day 1-5 | Appetite returns, fever resolves - expected early response |
| Day 7-14 | Check-in; effusion should begin resolving |
| Week 2 | Bloodwork: CBC, biochemistry, AGP or globulins |
| Week 4-6 | Repeat bloodwork; confirm improving trend |
| Week 8-10 | Repeat bloodwork; confirm remission |
| Day 84 | Final bloodwork before stopping - must be normal |
| Post-treatment: weeks 4, 8, 12 | Monitor for relapse |
Step 6 - Relapse Protocol
About 3% of Basmi-treated cats relapse. Signs: return of fever, loss of appetite, re-accumulation of effusion, neurological signs.
| Scenario | Action |
|---|---|
| Relapse during treatment | Increase dose by +2 mg/kg increments; consult vet |
| Relapse after completing treatment | Restart at 12-15 mg/kg SC (relapse dose) for 4-12 weeks |
| No improvement after 2 weeks at new dose | Increase to 15 mg/kg SC and reassess |
Step 7 - Storage of Vials
- Store at 2-8°C (refrigerated), away from light
- Do not freeze
- Once opened, use within the timeframe specified on the vial
- Check vial for clarity - do not use if cloudy or has visible particles
Important Notes
- Oral GS-441524 is now preferred by most international guidelines (iCatCare, ISFM, ABCD) over SC injectable GS-441524 because it is equally effective, less painful, and often cheaper. Injectable SC GS-441524 causes pain and skin reactions in many cats.
- Remdesivir IV is reserved for cats that cannot take oral medication (severely ill, cannot swallow).
- If using Basmi injectable and the cat shows persistent injection site pain, ulceration, or skin reactions - discuss switching to oral formulation with your vet.
- Never skip a dose - consistency is critical to preventing resistance and relapse.
For the most current Basmi FIP dosage calculator and vial selection, refer to Basmi FIP India. Always work with a licensed veterinarian for diagnosis confirmation and treatment adjustments.
enlist all the sign symptoms seen in this condition diease
Reading File
Searching the Web
FIP feline infectious peritonitis signs symptoms all forms wet dry ocular neurological complete list
Finding Sources
Here is a complete, organized list of all signs and symptoms seen in FIP (Feline Infectious Peritonitis), categorized by disease form:
Signs & Symptoms of FIP in Cats - Complete Listing
A. Early / Non-Specific Signs (ALL Forms)
These appear first, regardless of which form develops:
- Fever - persistent, fluctuating ("waxing and waning"), unresponsive to antibiotics
- Lethargy / depression - markedly reduced activity
- Anorexia / loss of appetite - often progressive
- Weight loss - gradual, sometimes severe
- Wasting / muscle loss (cachexia)
- Rough, dull, or unkempt coat
- Mild diarrhea (early, intermittent)
- Pale mucous membranes (from anemia)
- Generalized weakness
- Failure to thrive (especially in young cats/kittens)
B. Wet FIP (Effusive Form)
Caused by fluid leaking from inflamed blood vessels into body cavities:
Abdominal Effusion (most common)
- Pot-bellied / distended abdomen - fluid accumulation in peritoneal cavity
- Abdominal discomfort on palpation
- Rapid abdominal enlargement
- Fluid wave detectable on palpation ("ballottement")
Pleural Effusion (chest)
- Labored or rapid breathing (tachypnea, dyspnea)
- Open-mouth breathing
- Shallow, rapid respiratory effort
- Reduced lung sounds on auscultation
- Exercise intolerance
Pericardial Effusion (heart sac, less common)
- Muffled heart sounds
- Increased heart rate (tachycardia)
- Weak pulse
Other Wet FIP Signs
- Jaundice / icterus - yellow discoloration of skin, gums, and sclera (from liver involvement)
- Pale or icteric mucous membranes
- Enlarged lymph nodes (lymphadenopathy)
- Anemia - bluish gums (cyanosis) if severe
C. Dry FIP (Non-Effusive Form)
Granulomatous inflammation within organs - develops more slowly:
Abdominal Organ Involvement
- Abdominal mass or firm organ enlargement (kidney, mesenteric lymph nodes, liver)
- Vomiting
- Diarrhea (chronic)
- Polydipsia / polyuria (excess drinking and urination - from kidney infiltration)
- Jaundice (liver granulomas)
- Abdominal pain
Lymph Nodes
- Generalized or regional lymphadenopathy (enlarged lymph nodes)
Kidney Involvement
- Irregular, firm kidneys on palpation
- Protein in urine (proteinuria)
- Signs of renal failure in advanced cases (vomiting, lethargy, uremic breath)
Liver Involvement
- Hepatomegaly (enlarged liver)
- Jaundice
- Elevated liver enzymes on bloodwork (ALT, ALP)
D. Ocular FIP
One of the most distinctive presentations; can occur with wet or dry form:
- Uveitis - inflammation of the uveal tract (anterior, posterior, or panuveitis)
- Aqueous flare - cloudiness in the anterior chamber of the eye
- Hypopyon - yellow-white pus deposit in anterior chamber
- Hyphema - blood in the anterior chamber
- Keratic precipitates - white/yellow deposits on the cornea
- Iris color change - iris may appear discolored or irregular
- Synechiae - adhesions between iris and lens or cornea
- Chorioretinitis - inflammation of the retina and choroid
- Retinal hemorrhage or detachment
- Dilated, non-responsive pupils
- Blindness (partial or complete)
- Photophobia (sensitivity to light)
- Squinting (blepharospasm)
- Eye redness / conjunctival injection
- Cloudiness or opacity of the eye
E. Neurological FIP
Occurs when the virus invades the CNS; can appear with or without effusion:
Early Neurological Signs
- Subtle incoordination / stumbling
- Hesitation when jumping
- Generalized weakness
- Personality changes (increased aggression, confusion, withdrawn behavior)
Progressive Neurological Signs
- Ataxia - uncoordinated, wobbly gait (spinal cord involvement)
- Head tilt (vestibular dysfunction)
- Circling behavior
- Nystagmus - abnormal, rapid involuntary eye movements
- Tremors / muscle twitching
- Seizures (focal or generalized)
- Paresis or paralysis - partial or complete loss of limb function
- Hyperesthesia - exaggerated sensitivity to touch
- Incontinence (urinary or fecal) - loss of bladder/bowel control
- Nystagmus
- Opisthotonus - severe backward arching of the head/neck (in advanced cases)
- Loss of litter box habits
- Inability to walk or stand
- Cranial nerve deficits - facial asymmetry, abnormal eye position
F. Laboratory / Diagnostic Findings (Clinical Pathology Signs)
These are "signs" detectable on blood/fluid tests:
| Finding | Significance |
|---|---|
| Lymphopenia | Reduced lymphocyte count - very common |
| Non-regenerative anemia | Normocytic, normochromic |
| Neutrophilia | Elevated white cell count |
| Hyperglobulinemia | Elevated globulins (>35 g/L) |
| Hypoalbuminemia | Low albumin |
| A:G ratio <0.4 | Albumin:Globulin ratio - strongly suggestive |
| Elevated bilirubin | Jaundice/icterus |
| Elevated ALT, ALP | Liver involvement |
| Elevated BUN/creatinine | Kidney involvement |
| Elevated AGP (alpha-1 acid glycoprotein) | Acute phase protein >1.5 mg/mL |
| Elevated SAA (serum amyloid A) | Acute phase protein |
| Effusion: high protein, low cell count | "Sticky," yellow, viscous fluid |
| Rivalta test positive | Specific for FIP effusion |
| FCoV RNA positive (PCR in effusion/CSF) | Confirms viral presence |
G. Signs by Age Group
| Age | Notable Patterns |
|---|---|
| Kittens (<1 year) | Failure to thrive, pot belly, rapid progression |
| Young cats (1-3 years) | Most commonly affected; rapid wet form |
| Cats >13 years | Higher risk due to immunosenescence; often dry form |
| Purebred cats | Higher incidence (Abyssinian, Bengal, Birman, Ragdoll, Devon Rex, etc.) |
Quick Summary Table
| Form | Key Signs |
|---|---|
| All forms (early) | Fever, lethargy, anorexia, weight loss, rough coat |
| Wet FIP | Pot belly, breathing difficulty, jaundice, tachycardia |
| Dry FIP | Organ masses, vomiting, polyuria/polydipsia, jaundice |
| Ocular FIP | Uveitis, hypopyon, aqueous flare, blindness, hyphema |
| Neurological FIP | Ataxia, seizures, head tilt, nystagmus, paralysis, tremors |
Sources: Cornell Feline Health Center | PetMD FIP Overview | AAFP/EveryCat FIP Diagnosis Guidelines 2022 | ABCD FIP Guideline 2025
This is a shared conversation. Sign in to Orris to start your own chat.